SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:42b36459-f626-480d-a0be-379b916b24ed"
 

Search: onr:"swepub:oai:lup.lub.lu.se:42b36459-f626-480d-a0be-379b916b24ed" > Toward allele-speci...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006446naa a2200901 4500
001oai:lup.lub.lu.se:42b36459-f626-480d-a0be-379b916b24ed
003SwePub
008201102s2020 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/42b36459-f626-480d-a0be-379b916b24ed2 URI
024a https://doi.org/10.1126/scitranslmed.abb70862 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Prudencio, Mercedesu Mayo Clinic Florida4 aut
2451 0a Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3
264 1b American Association for the Advancement of Science (AAAS),c 2020
520 a Spinocerebellar ataxia type 3 (SCA3), caused by a CAG repeat expansion in the ataxin-3 gene (ATXN3), is characterized by neuronal polyglutamine (polyQ) ATXN3 protein aggregates. Although there is no cure for SCA3, gene-silencing approaches to reduce toxic polyQ ATXN3 showed promise in preclinical models. However, a major limitation in translating putative treatments for this rare disease to the clinic is the lack of pharmacodynamic markers for use in clinical trials. Here, we developed an immunoassay that readily detects polyQ ATXN3 proteins in human biological fluids and discriminates patients with SCA3 from healthy controls and individuals with other ataxias. We show that polyQ ATXN3 serves as a marker of target engagement in human fibroblasts, which may bode well for its use in clinical trials. Last, we identified a single-nucleotide polymorphism that strongly associates with the expanded allele, thus providing an exciting drug target to abrogate detrimental events initiated by mutant ATXN3. Gene-silencing strategies for several repeat diseases are well under way, and our results are expected to improve clinical trial preparedness for SCA3 therapies.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
700a Garcia-Moreno, Hector4 aut
700a Jansen-West, Karen Ru University of Geneva4 aut
700a Al-Shaikh, Rana Hannau Nordsjællands Hospital4 aut
700a Gendron, Tania Fu University of Geneva4 aut
700a Heckman, Michael Gu Mayo Clinic Minnesota4 aut
700a Spiegel, Matthew Ru Mayo Clinic Minnesota4 aut
700a Carlomagno, Yariu University of Geneva4 aut
700a Daughrity, Lillian Mu University of Geneva4 aut
700a Song, Yupingu University of Geneva4 aut
700a Dunmore, Judith Au University of Geneva4 aut
700a Byron, Natalieu University of Geneva4 aut
700a Oskarsson, Björnu Nordsjællands Hospital4 aut
700a Nicholson, Katharine A4 aut
700a Staff, Nathan Pu Nordsjællands Hospital4 aut
700a Gorcenco, Sorinau Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)so1444go
700a Puschmann, Andreasu Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)med-aps
700a Lemos, Joãou Center for Neuroscience and Cell Biology, University of Coimbra4 aut
700a Januário, Cristinau Center for Neuroscience and Cell Biology, University of Coimbra4 aut
700a LeDoux, Mark S4 aut
700a Friedman, Joseph H4 aut
700a Polke, James4 aut
700a Labrum, Robin4 aut
700a Shakkottai, Vikramu Western Michigan University4 aut
700a McLoughlin, Hayley Su Western Michigan University4 aut
700a Paulson, Henry Lu Western Michigan University4 aut
700a Konno, Takuyau Niigata University4 aut
700a Onodera, Osamuu Niigata University4 aut
700a Ikeuchi, Takeshiu Niigata University4 aut
700a Tada, Mariu Niigata University4 aut
700a Kakita, Akiyoshiu Niigata University4 aut
700a Fryer, John D4 aut
700a Karremo, Christinu Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)med-crk
700a Gomes, Inêsu Center for Neuroscience and Cell Biology, University of Coimbra4 aut
700a Caviness, John Nu Nordsjællands Hospital4 aut
700a Pittelkow, Mark R4 aut
700a Aasly, Janu Norwegian University of Science and Technology4 aut
700a Pfeiffer, Ronald Fu Oregon Health & Science University4 aut
700a Veerappan, Venkau Oregon Health & Science University4 aut
700a Eggenberger, Eric Ru Nordsjællands Hospital4 aut
700a Freeman, William Du Nordsjællands Hospital4 aut
700a Huang, Josephine Fu Nordsjællands Hospital4 aut
700a Uitti, Ryan Ju Nordsjællands Hospital4 aut
700a Wierenga, Klaas Ju Nordsjællands Hospital4 aut
700a Marin Collazo, Iris Vu Nordsjællands Hospital4 aut
700a Tipton, Philip Wu Nordsjællands Hospital4 aut
700a van Gerpen, Jay Au University of South Alabama4 aut
700a van Blitterswijk, Markau University of Geneva4 aut
700a Bu, Guojunu University of Geneva4 aut
700a Wszolek, Zbigniew Ku Nordsjællands Hospital4 aut
700a Petrucelli, Leonardu Mayo Clinic Florida4 aut
710a Mayo Clinic Floridab University of Geneva4 org
710a et al.
773t Science Translational Medicined : American Association for the Advancement of Science (AAAS)g 12:566q 12:566x 1946-6242x 1946-6234
856u http://dx.doi.org/10.1126/scitranslmed.abb7086y FULLTEXT
856u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927160
8564 8u https://lup.lub.lu.se/record/42b36459-f626-480d-a0be-379b916b24ed
8564 8u https://doi.org/10.1126/scitranslmed.abb7086

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view